Biogen Strikes A Deal With Isis For Antisense Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.